Ronapreve Euroopan unioni - puola - EMA (European Medicines Agency)

ronapreve

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - odporne surowicy i immunoglobuliny, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. zobacz rozdziały 4. 4 i 5.

Sapropterin Dipharma Euroopan unioni - puola - EMA (European Medicines Agency)

sapropterin dipharma

dipharma arzneimittel gmbh - Сапроптерин дигидрохлорид - fenyloketonurie - inne przewodu pokarmowego i przemianę materii narzędzia, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.